News

Following clearance of the investigational new drug (IND) application by the FDA, Pluristem will initiate Phase I dose ranging clinical trials during the first half of 2009 at

The PER.C6 platform allows ProFibrix to manufacture recombinant human fibrinogen at levels that support the development and commercial rollout of new products. The company’s lead product Fibrocaps is

Novartis has announced that the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS, BARDA) has awarded Novartis Vaccines a contract for up

She previously worked for Focus Diagnostics/Quest for over 20 years in a wide-ranging role encompassing sales and marketing, technical advisory and business development. Stephen Little, chief executive officer

Results of operations Consolidated net sales for Biomerica were $2,314,920 for the first six months of fiscal 2009 as compared to $2,367,599 for the same period in the

Bland also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott. Bland received his B.S. and his M.B.A.

Under this agreement, Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467. This peptide therapeutic has completed an initial clinical study

MacuCLEAR is developing MC 1101 for the treatment and prevention of the progression of age related macular degeneration (AMD). Mystic Pharmaceuticals said that it has developed a novel

The letter outlined questions that the FDA identified during its review of the new drug application (NDA) for over-the-counter (OTC) Zegerid. Santarus said that it is in regular